Science Explorer Back to mapMap
Discussion
Topic · Cancer Research

Protease and Inhibitor Mechanisms

Protease and Inhibitor Mechanisms is a research topic within Cancer Research. Science Explorer counts 38k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the multifaceted roles of matrix metalloproteinases (MMPs) in cancer progression, angiogenesis, inflammation regulation, and extracellular matrix remodeling. It also delves into the potential of MMPs as therapeutic targets for cancer therapy and their involvement in various physiological processes such as cell signaling and tissue remodeling.

  • Matrix Metalloproteinases
  • Tissue Inhibitors of Metalloproteinases
  • Cancer Progression
  • Angiogenesis
  • Extracellular Matrix Remodeling
  • Protease Inhibition
  • Inflammation Regulation
  • Cell Signaling
  • Metastasis
  • Extracellular Matrix
Research works
38k
fractional, since 1950
In the world top 10%
3.8k
per year above
Top-10% rate
9.9%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-3%
the tick is no change
Largest producer
China
38% of the 10 largest, 2022-now
Protease and Inhibitor Mechanisms

Which countries lead Protease and Inhibitor Mechanisms research?

By volume, China and the United States publish the most (1k and 681 works in 2022-now).

By volume, 2022-now

  1. 1 China 1k works
  2. 2 United States 681 works
  3. 3 India 187 works
  4. 4 Germany 163 works
  5. 5 Japan 147 works
  6. 6 United Kingdom 118 works
  7. 7 Italy 107 works
  8. 8 Spain 89 works
  9. 9 France 81 works
  10. 10 Türkiye 81 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 38.5%United States: 25.3%India: 7.0%Germany: 6.1%6 others listed: 23.2%38%largest
China1,035 · 38.5%United States681 · 25.3%India187 · 7.0%Germany163 · 6.1%6 others listed624 · 23.2%

Shares of the rows listed above, not of the whole node.

Which institutions lead Protease and Inhibitor Mechanisms research?

By volume in 2022-now, Shanghai Jiao Tong University publishes the most Protease and Inhibitor Mechanisms research, followed by Sichuan University and Harvard University.

By volume, 2022-now

  1. 1 Shanghai Jiao Tong UniversityChina 27 works
  2. 2 Sichuan UniversityChina 26 works
  3. 3 Harvard UniversityUnited States 24 works
  4. 4 University of North Carolina at Chapel HillUnited States 22 works
  5. 5 Nanjing Medical UniversityChina 22 works
  6. 6 Sun Yat-sen UniversityChina 20 works
  7. 7 Capital Medical UniversityChina 19 works
  8. 8 Centre National de la Recherche ScientifiqueFrance 18 works
  9. 9 Russian Academy of SciencesRussia 18 works
  10. 10 InsermFrance 18 works

Who are the leading researchers in Protease and Inhibitor Mechanisms?

The most-cited researchers publishing on Protease and Inhibitor Mechanisms include Stacey L. Gabriel, John J.V. McMurray and Hermann Brenner.

  1. 1 Stacey L. Gabriel United States 402k citations
  2. 2 John J.V. McMurray United Kingdom 349k citations
  3. 3 Hermann Brenner Germany 343k citations
  4. 4 Emelia J. Benjamin United States 341k citations
  5. 5 Jun Wang China 340k citations
  6. 6 Mika Kivimäki United Kingdom 318k citations
  7. 7 Graeme J. Hankey Australia 316k citations
  8. 8 Gregory Y.H. Lip United Kingdom 311k citations
  9. 9 Matthias Mann Germany 308k citations
  10. 10 Róbert Langer United States 303k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Protease and Inhibitor Mechanisms?

The most cited paper in Protease and Inhibitor Mechanisms is "Tissue Plasminogen Activator for Acute Ischemic Stroke" (The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study G, 1995), with 11,752 citations. Next come "The pathogenesis of atherosclerosis: a perspective for the 1990s" (10,703) and "New functions for the matrix metalloproteinases in cancer progression" (6,127).

Most cited papers
#PaperReleasedCitations
1 Tissue Plasminogen Activator for Acute Ischemic Stroke The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study G · New England Journal of Medicine 14 Dec 1995 11,752
2 The pathogenesis of atherosclerosis: a perspective for the 1990s Russell Ross · Nature Apr 1993 10,703
3 New functions for the matrix metalloproteinases in cancer progression Mikala Egeblad, Zena Werb · Nature reviews. Cancer Review Mar 2002 6,127
4 Matrix Metalloproteinases: Regulators of the Tumor Microenvironment Kai Kessenbrock, Vicki Plaks, Zena Werb · Cell Open access Apr 2010 5,146
5 Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Robert Visse, Hideaki Nagase · Circulation Research Open access May 2003 4,573
All 100 most cited papers, with filters and sorting

Where is Protease and Inhibitor Mechanisms research done?

The largest centres of Protease and Inhibitor Mechanisms research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Nanjing (China).

Largest cities, 2022-now

  1. 1 BeijingChina 100 works
  2. 2 ShanghaiChina 86 works
  3. 3 GuangzhouChina 71 works
  4. 4 NanjingChina 44 works
  5. 5 WuhanChina 38 works
  6. 6 ChengduChina 38 works
  7. 7 TokyoJapan 36 works
  8. 8 ParisFrance 35 works
  9. 9 LondonUnited Kingdom 32 works
  10. 10 HangzhouChina 32 works
See Protease and Inhibitor Mechanisms on the map

Where is the best place to study Protease and Inhibitor Mechanisms?

Among universities, judged by research, Harvard University, Southern Medical University and Sichuan University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%30%mean 16.18%fractional works in this field (log) →share of work in the world top 10% →Southern Medical Uni…Sichuan UniversityHarvard UniversityRoyal College of Sur…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 70.813.0%2.3×24 -9.8%
2Southern Medical UniversityChina 70.424.0%8.1×17 +68.1%
3Sichuan UniversityChina 66.917.4%3.4×26 +113.1%
4Royal College of Surgeons in IrelandIreland 62.59.1%45.4×15 +141.1%
5Shanghai Jiao Tong UniversityChina 61.214.2%2.8×27 +10.0%
6Wuhan UniversityChina 56.020.3%3.0×14 +18.0%
7Xiamen UniversityChina 55.123.8%2.9×8 +10.1%
8Capital Medical UniversityChina 53.014.6%5.4×19 +7.3%
9Nanjing Medical UniversityChina 51.811.3%7.3×22 +2.7%
10Guangzhou Medical UniversityChina 50.214.1%10.2×12 +73.9%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Protease and Inhibitor Mechanisms, country by country

Is Protease and Inhibitor Mechanisms research growing?

Output in 2022-2025 was 3% lower than in 2018-2021, peaking in 2012.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Protease and Inhibitor Mechanisms as a percentage of every work published that year, 0.015% in 2024.

still counting0.050%0.10%Protease and Inhibitor Mechanisms0.016% in 202519801990200020102020

Fractional works of Protease and Inhibitor Mechanisms over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Protease and Inhibitor Mechanisms10.5% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Protease and Inhibitor Mechanisms. Posts are plain text and can be reported.